HLTH Corp. to merge with WebMD

Share this article:

HLTH Corporation announced plans to merge with its  WebMD Health subsidiary in a move that could make the combined company an attractive takeover target for larger Internet companies such as Google.

HLTH announced that it would merge into its 84%-owned subsidiary, WebMD, in a $2.3 billion deal. Under terms of the transaction, each outstanding share of HLTH common stock will be converted into shares of WebMD common stock and $6.89 in cash. The transaction is expected to close in the second or third quarter of 2008.

WebMD's senior management team is expected to continue to lead the organization under current president and CEO Wayne Gattinella.

Meanwhile, WebMD Health Corp., which provides health information through its website, said profit soared in the fourth quarter of 2007 due to a hefty tax gain and strong demand for online services.

WebMD's revenue for the fourth quarter and full year excluded about $1 million and $4 million, respectively, related to its offline professional medical reference and textbook publication business, which was sold on Dec. 31. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?